Related Experiment Video

Updated: May 12, 2026

Measurement of Myocardial Lactate Production for Diagnosis of Coronary Microvascular Spasm
06:18

Measurement of Myocardial Lactate Production for Diagnosis of Coronary Microvascular Spasm

Published on: September 17, 2021

Higher serum uric acid and lipoprotein(a) are correlated with coronary spasm

Masami Nishino1, Naoki Mori, Takahiro Yoshimura

  • 1Division of Cardiology, Osaka Rosai Hospital, 1179-3 Nagasone-cho, Sakai, Osaka, 591-8025, Japan, mnishino@orh.go.jp.

Heart and Vessels
|April 5, 2013
PubMed

Insights

Serum uric acid and lipoprotein(a) are significantly elevated in patients with vasospastic angina (VSA). These markers are independently correlated with VSA, suggesting potential therapeutic targets for managing this condition.

Area of Science:

  • Cardiology
  • Biochemistry

Background:

  • Endothelial dysfunction is a primary cause of vasospastic angina (VSA).
  • Serum uric acid and lipoprotein(a) have been linked to endothelial dysfunction.

Purpose of the Study:

  • To investigate the correlation between serum uric acid, lipoprotein(a), and VSA.
  • To identify potential biomarkers for VSA diagnosis and management.

Main Methods:

  • A cohort of 441 patients with suspected VSA underwent acetylcholine provocation testing.
  • Serum levels of uric acid, lipoprotein(a), hs-CRP, and other markers were compared between VSA and atypical chest pain (ACP) groups.
  • Multivariate analyses were performed to identify independent predictors of VSA.

Main Results:

  • Uric acid, hs-CRP, and lipoprotein(a) levels were significantly higher in the VSA group compared to the ACP group.
  • Multivariate analysis confirmed uric acid and lipoprotein(a) as significant independent markers for VSA.
  • No significant differences were observed in other tested parameters between the groups.

Conclusions:

  • Serum uric acid and lipoprotein(a) are correlated with VSA.
  • Lowering uric acid and lipoprotein(a) may be a potential therapeutic strategy for VSA management.

More Related Videos

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...